Pegcetacoplan API is a complex PEGylated peptide therapeutic substance designed to inhibit the complement system by targeting complement component C3. It is a symmetrical molecule consisting of two identical pentadecapeptides covalently attached to the ends of a linear 40 kDa polyethylene glycol (PEG) chain. The FDA describes pegcetacoplan as a complement inhibitor with an approximate molecular weight of 43.5 kDa.
Pegcetacoplan is a specialized peptide-based pharmaceutical substance with applications in complement-mediated disorders. Its structure combines peptide sequences responsible for C3 binding with PEGylation intended to provide extended residence time and improve the molecule's pharmaceutical properties. The peptide portions contain modified amino-acid components including 1-methyl-L-tryptophan and amino(ethoxyethoxy)acetic acid (AEEA).
The recognized CAS Registry Number for pegcetacoplan is 2019171-69-6. The FDA substance database also identifies pegcetacoplan under synonyms including APL-2 and Empaveli.
Pegcetacoplan is a macromolecular peptide-PEG conjugate rather than a conventional small-molecule API. The FDA-approved product labeling gives the molecular formula as C₁₉₇₀H₃₈₄₈N₅₀O₉₄₇S₄ and an approximate molecular weight of 43.5 kDa.
Because pegcetacoplan contains a large PEG component and peptide moieties, conventional small-molecule parameters such as a single fixed melting point or a simple low-molecular-weight molecular-weight value are not appropriate for describing the substance. The FDA characterizes the drug substance as a hygroscopic solid and notes its complex peptide-conjugate structure.
Pegcetacoplan is a complement C3 inhibitor. Its pharmacological activity results from binding to complement component C3 and interfering with activation of the complement cascade. The approved drug product EMPAVELI contains pegcetacoplan for subcutaneous administration, while pegcetacoplan is also used in the ophthalmic product SYFOVRE for intravitreal administration.
For pharmaceutical development and API manufacturing, appropriate characterization of identity, purity, peptide-related impurities, aggregation, moisture, and other critical quality attributes is particularly important because pegcetacoplan is a complex biologic/peptide-PEG molecule. FDA review documents specifically identify sterility, aggregation and particulates, tonicity, peptide-related impurities, and stability as important quality considerations for the drug product.
Pegcetacoplan API manufacturing requires specialized capabilities for peptide synthesis, conjugation, purification, analytical characterization, and control of macromolecular quality attributes. A qualified Pegcetacoplan API manufacturer in India should maintain appropriate quality systems and validated analytical procedures suitable for complex peptide-based pharmaceutical substances.
Quality evaluation may include identity testing, chromatographic purity, peptide mapping, molecular-mass characterization, residual impurities, moisture determination, aggregation assessment, and other product-specific quality attributes. Since pegcetacoplan is a complex biological/peptide conjugate, final release specifications should be established according to the applicable validated manufacturing and analytical process rather than applying generic small-molecule API limits.
Pegcetacoplan is an important complement-pathway therapeutic molecule with established pharmaceutical applications. Its distinctive PEGylated peptide structure makes it suitable for specialized drug-development programs involving complement inhibition. Reliable manufacturing requires controlled synthesis and conjugation processes, appropriate purification technologies, and comprehensive analytical characterization.
For pharmaceutical companies, research organizations, and formulation-development programs seeking Pegcetacoplan API in India, product quality, traceability, analytical documentation, controlled manufacturing processes, and consistency between batches are essential considerations.
Note: Pegcetacoplan is a complex peptide-PEG drug substance. Numerical release specifications such as assay, individual impurity, total impurities, water content, and residue on ignition are not universal public specifications and should not be represented as generic values without an applicable approved or manufacturer-specific specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.2% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |